We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: Auto hematopoietic cell transplant not useful for mantle cell lymphoma with undetectable residual illness
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > Auto hematopoietic cell transplant not useful for mantle cell lymphoma with undetectable residual illness
Auto hematopoietic cell transplant not useful for mantle cell lymphoma with undetectable residual illness
Health

Auto hematopoietic cell transplant not useful for mantle cell lymphoma with undetectable residual illness

Last updated: December 7, 2024 12:01 pm
Editorial Board Published December 7, 2024
Share
SHARE

Autologous hematopoietic cell transplant (auto-HCT) is just not useful for sufferers with mantle cell lymphoma (MCL) in first full remission (CR) with undetectable minimal residual illness (uMRD), in keeping with a examine to be offered on the annual assembly of the American Society of Hematology, held from Dec. 7 to 10 in San Diego.

Timothy S. Fenske, M.D., from the Medical School of Wisconsin in Milwaukee, and colleagues carried out a four-arm trial involving sufferers with MCL between 18 and 70 years of age and in first remission. Sufferers in CR with uMRD at 1 in 10-6 sensitivity (uMRD6) have been randomly assigned to arm A (auto-HCT + three years of upkeep rituximab [MR]) or arm B (three years of MR alone). Sufferers with MRD-positive CR or MRD-indeterminate CR each acquired auto-HCT + three years of MR (arms C and D, respectively). The first finish level was to match survival in arms A and B.

From August 2017 to July 2024, 257, 259, 49, and 85 sufferers have been enrolled in arms A, B, C, and D, respectively. The researchers discovered that the estimated general survival hazard ratios for arms A and B in all randomized and treated-as-assigned sufferers (516 and 375, respectively) have been 1.11 (95% confidence interval, 0.71 to 1.74; P = 0.66) and 1.00 (95% confidence interval, 0.58 to 1.74; P = 0.99), and crossed the boundary for futility. Three-year general survival was 82.1 and 82.7%, respectively, for arms A and B in all randomly assigned sufferers, and 86.2 and 84.8%, respectively, in these handled as assigned.

“In this interim analysis, in the era of highly effective induction and maintenance regimens, MCL patients in first CR with uMRD6 did not benefit from consolidative auto-HCT,” the authors write.

A number of authors disclosed ties to the pharmaceutical and biotechnology industries.

© 2024 HealthDay. All rights reserved.

Quotation:
Auto hematopoietic cell transplant not useful for mantle cell lymphoma with undetectable residual illness (2024, December 6)
retrieved 7 December 2024
from https://medicalxpress.com/information/2024-12-auto-hematopoietic-cell-transplant-beneficial.html

This doc is topic to copyright. Aside from any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.

You Might Also Like

Can AI be your therapist? Not fairly but, says new examine

Computational fashions discover how areas of the visible cortex collectively symbolize visible data

Folks with ‘younger brains’ outlive ‘old-brained’ friends, scientists discover

Which components have an effect on the success of in style prescription weight reduction medication in people?

Wholesome plant-based weight loss plan might assist shield in opposition to inflammatory bowel illness

TAGGED:AutobeneficialcelldiseasehematopoieticLymphomamantleresidualtransplantundetectable
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Up to date Artists Use the Rug as a Car for Expression on the Museum of Craft and Design
Art

Up to date Artists Use the Rug as a Car for Expression on the Museum of Craft and Design

Editorial Board January 9, 2025
Dozens of White Supremacists Arrested in Idaho Had Planned to Riot, Authorities Say
Biden Emerges From Isolation Again After Second Negative Coronavirus Test
A New York Homecoming for the ‘Queen of Hoops’
What’s Left for the Weeknd to Conquer?

You Might Also Like

AI–based mostly check detects early indicators of osteoporosis from X-ray pictures
Health

AI–based mostly check detects early indicators of osteoporosis from X-ray pictures

July 9, 2025
ADAM10 protein ranges in blood linked to early Alzheimer’s and genetic danger components
Health

ADAM10 protein ranges in blood linked to early Alzheimer’s and genetic danger components

July 9, 2025
Information present teclistamab can profit many a number of myeloma sufferers who would have been ineligible for pivotal trial
Health

Information present teclistamab can profit many a number of myeloma sufferers who would have been ineligible for pivotal trial

July 9, 2025
Most cancers-fighting herpes virus proven to be an efficient remedy for some superior melanoma
Health

Most cancers-fighting herpes virus proven to be an efficient remedy for some superior melanoma

July 9, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?